Abbott Laboratories Reports Quarter and Nine Months Ended December 31, 2024
Abbott Laboratories has reported unaudited financial results for the quarter and nine months ended December 31, 2024. The company’s stock price has increased despite a decline in the market.
Key Highlights
- The company’s diabetes business has contributed to growth in revenue
- Foreign exchange issues have posed a challenge to the company’s performance
Financial Results
Abbott Laboratories has reported the following unaudited financial results for the quarter and nine months ended December 31, 2024:
- Revenue: $[insert revenue figure]
- Net income: $[insert net income figure]
- Foreign exchange impact: $[insert foreign exchange impact figure]
Business Performance
The company’s expanding diabetes business has been a significant contributor to growth in revenue. However, foreign exchange issues have posed a challenge to the company’s performance.
Next Steps
The company’s unaudited financial results for the quarter and nine months ended December 31, 2024, may provide further insight into its performance.